Management of childhood malignant peripheral nerve sheath tumor.
Malignant peripheral nerve sheath tumor (MPNST) is rare, but is one of the most frequent non-rhabdomyosarcoma soft-tissue sarcomas in the pediatric population. These tumors occur most frequently at axial sites and are characterized by local aggressiveness and a propensity to metastasize. They are often associated with neurofibromatosis type 1 (NF-1): the lifetime risk of patients with NF-1 developing MPNST has been estimated at 8-13%, compared with 0.001% in the general population. Because of the rarity of this tumor, little information is available on its clinical management, particularly in the pediatric age group. In a recent report on the clinical findings and treatment outcomes from a large number of children and adolescents with MPNST in an Italian and German series, less satisfactory overall outcomes than those for other pediatric sarcomas were described. Therefore, the approach to the treatment of patients with MPNST should be aggressive and risk adapted, and is necessarily complex. Patients should be referred to selected institutions with adequate experience in treating soft-tissue sarcomas, and with the multidisciplinary skills for enrolling patients in clinical trials. Surgical resection represents the mainstay of treatment, while the role of adjuvant treatment is not yet clear. Post-operative radiotherapy seems to have a role in improving local control, although the potential morbidity of irradiation should be taken into account, particularly when treating children. Although lack of local control is the major cause of treatment failure, MPNST may give rise to distant metastases. These tumors are usually considered as having uncertain chemosensitivity, but recent evidence suggests that there may be a role for chemotherapy in patients with a high-grade histology. For the near future, our hopes lie in the development of novel tailored therapies directed specifically against the molecular targets of the neoplastic cells: soft-tissue sarcomas seem particularly promising candidates for targeted therapy.
Ferrari
Andrea
A
Pediatric Oncology Unit, Istituto Nazionale Tumori, Milan, Italy.
Bisogno
Gianni
G
Carli
Modesto
M
D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D016503:Drug Delivery Systems; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D009367:Neoplasm Staging; D018317:Nerve Sheath Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D009456:Neurofibromatosis 1 / Q000150:complications; D011379:Prognosis; D016896:Treatment Outcome
D000970:Antineoplastic Agents
Cancer. 1981 May 15;47(10):2503-9
6791802
Cancer. 1986 Mar 15;57(6):1225-9
3080222
J Clin Oncol. 2001 Mar 1;19(5):1238-47
11230464
Am J Hum Genet. 2003 May;72(5):1288-92
12660952
Cancer. 1973 Jan;31(1):184-90
4683036
Lab Invest. 2001 Jun;81(6):833-44
11406645
Nature. 1992 Apr 23;356(6371):713-5
1570015
Am J Med Genet. 1997 May 16;70(2):138-43
9128932
J Med Genet. 2002 May;39(5):311-4
12011145
J Clin Invest. 2000 May;105(9):1233-41
10791998
Cancer. 1993 Feb 15;71(4):1247-53
8435801
Expert Rev Anticancer Ther. 2005 Apr;5(2):307-18
15877527
Cancer. 2007 Apr 1;109(7):1406-12
17330850
J Child Neurol. 2002 Aug;17(8):548-54; discussion 571-2, 646-51
12403552
JAMA. 1997 Jul 2;278(1):51-7
9207339
Cancer. 1988 Jan 15;61(2):209-20
3275486
J Neurol Neurosurg Psychiatry. 2000 Mar;68(3):353-7
10675220
Lancet. 2002 Jun 29;359(9325):2235-41
12103287
N Engl J Med. 1986 Apr 17;314(16):1010-5
3083258
Genes Chromosomes Cancer. 1994 Aug;10(4):250-5
7522538
Cancer. 2006 Sep 1;107(5):1065-74
16881077
J Clin Oncol. 1999 Dec;17(12):3697-705
10577841
J Clin Oncol. 2005 Jun 20;23(18):4031-8
15767644
Cancer. 1963 Aug;16:1015-27
14050005
Cancer. 1993 Nov 1;72(9):2746-54
8402499
Lancet. 1997 Dec 6;350(9092):1647-54
9400508
Med Pediatr Oncol. 1998 Apr;30(4):201-9
9473754
J Pediatr Hematol Oncol. 1999 Nov-Dec;21(6):509-13
10598662
Mod Pathol. 1995 Sep;8(7):705-10
8539226
Pediatr Blood Cancer. 2005 Aug;45(2):128-34
15852434
Med Pediatr Oncol. 1994;22(2):78-83
8259105
J Clin Oncol. 2005 Nov 20;23(33):8422-30
16293873
J Clin Oncol. 2002 Aug 1;20(15):3225-35
12149295
Ann Surg Oncol. 1995 Nov;2(6):524-9
8591083
Clin Orthop Relat Res. 2004 Sep;(426):69-73
15346054
J Clin Oncol. 1997 Jan;15(1):350-62
8996162
Am J Surg Pathol. 1992 Jul;16(7):694-707
1530109
Pediatr Neurol. 2005 Apr;32(4):221-8
15797177
Cancer. 1990 Sep 15;66(6):1253-65
2119249
Clin Cancer Res. 2003 Sep 15;9(11):4132-8
14519636
Cell. 1990 Aug 10;62(3):599-608
2116237
J Clin Oncol. 2005 Jun 20;23(18):4021-30
15767645
Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):351-60
9788415
Eur J Surg Oncol. 1995 Feb;21(1):78-82
7851559
J Clin Oncol. 1999 Apr;17(4):1219
10561182
Genes Chromosomes Cancer. 1999 Dec;26(4):376-80
10534774
Cancer. 1986 May 15;57(10):2006-21
3082508
J Clin Oncol. 1998 Jan;16(1):197-203
9440743
Cancer. 1987 Jan 1;59(1):1-5
3791140
Nat Rev Cancer. 2005 Jul;5(7):557-64
16069817
J Clin Oncol. 2006 Jan 20;24(3):507-16
16421428
Hum Mutat. 1994;4(2):83-101
7981724
Science. 1990 Jul 13;249(4965):181-6
2134734
Genes Chromosomes Cancer. 1991 Jan;3(1):62-70
1906341
Cancer Cell. 2005 Jan;7(1):65-75
15652750